GPX4 and ovarian cancer: In ovarian cancers, OCCC cells exhibited significantly higher sensitivity to GPX4 inhibitors and lower sensitivity to paclitaxel than other ovarian carcinoma lines in average in CTRP (Supplementary Fig. 2d).